A blood test that can detect cancer before any symptoms appear, and save lives as a result, is sometimes referred to as the “holy grail” of cancer research. Are we there yet?
Immunotherapy is now part of standard of care for some types of triple negative breast cancer, with much more research ongoing.
A vaccine aimed at preventing breast cancer in healthy individuals is expected to begin testing soon in a Phase I clinical trial.
My top three takeaways from the 2020 San Antonio Breast Cancer Symposium.
This year we’ve seen some encouraging news with approvals of a targeted therapy and an immunotherapy for triple negative breast cancer.
Top “take-home” highlights from the 2019 San Antonio Breast Cancer Symposium.
There were some noteworthy developments this year in targeted therapies for hormone receptor-positive breast cancer.
Findings from the TAILORx clinical trial will help personalize treatment decisions for many patients with early stage breast cancer.
Researchers are working on ways to make immune system therapies more effective for more cancer patients.
Cancer research stories worth following this winter included reports on new approaches to immunotherapy currently being tested in clinical trials.